Pelthos Therapeutics
PTHSPelthos Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative dermatology and pain management therapies.
Earnings
Next report
Nov 12, 2026 (in 2 months)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
Profile
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative dermatology and pain management therapies. The company leverages its proprietary NITRICIL technology platform to deliver nitric oxide-based treatments for viral skin infections and is advancing a pipeline of non-opioid pain therapeutics targeting the NaV1.7 sodium ion channel.
The company holds a unique position as the provider of the first FDA-approved at-home prescription treatment for molluscum contagiosum and maintains a proprietary manufacturing facility for its nitric oxide API.
FAQ
- What is Pelthos Therapeutics's market cap?
- Pelthos Therapeutics (PTHS) has a market capitalization of $102.5M and trades on AMEX.
- What is Pelthos Therapeutics's revenue and profitability?
- Pelthos Therapeutics generated $27.7M in trailing twelve-month revenue with a net loss of $51.6M, representing a net margin of -186.2%. Gross margin stands at 79.6%, with free cash flow of -$16.8M. These figures are based on the Q1 2026 filing.
- Who are Pelthos Therapeutics's competitors?
- Pelthos Therapeutics's key competitors include Verrica Pharmaceuticals Inc., Scilex Holding Company Common Stock, Journey Medical Corporation Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Pelthos Therapeutics partner with?
- Pelthos Therapeutics's notable partners include Ligand Pharmaceuticals, Inc., Orion Corporation, Horizon Technology Finance Corporation, and others.
- What subsidiaries does Pelthos Therapeutics have?
- Pelthos Therapeutics's subsidiaries include LNHC, Inc., Channel Therapeutics Corporation.
- Where is Pelthos Therapeutics headquartered?
- Pelthos Therapeutics is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2024.
